An article from Technology Networks discusses, "Breath Test for Cancer: Biomarker Screening is Underway."
The article, written by Michele Wilson, features a discussion with Chris Claxton, our Head of Investor Relations, detailing the mission of Owlstone Medical and an overview of the Breath Biopsy® platform. It concludes with a summary of breath research field and its potential to act as a diagnostic tool across a wide range of diseases.
The thought that compounds in the breath could be measured and assessed to diagnose different aspects of pathology is an exciting prospect.
If you want to learn more about how Owlstone Medical's Breath Sampling and Analysis technology and Services are being utilized in early detection and precision medicine, why not download our free ebook: Breath Biopsy: The Complete Guide?